Le Lézard
Classified in: Business
Subject: ATY

CGNT ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of May 1, 2023 in the Class Action Filed on Behalf of Cognyte Software Ltd. Shareholders


NEW YORK, March 28, 2023 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Cognyte Software Ltd. (NASDAQ: CGNT) alleging that the Company violated federal securities laws.

This lawsuit is on behalf of all purchasers of Cognyte common stock between February 2, 2021 and June 28, 2022, inclusive.
Lead Plaintiff Deadline: May 1, 2023
No obligation or cost to you.

Learn more about your recoverable losses in CGNT:
https://www.kleinstocklaw.com/pslra-1/cognyte-lawsuit-loss-submission-form?id=37687&from=4

Cognyte Software Ltd. NEWS - CGNT NEWS

CLASS ACTION CASE DETAILS: The filed complaint alleges that Cognyte Software Ltd. made materially false and/or misleading statements and/or failed to disclose that: 1) Cognyte created, distributed, and provided reconnaissance tools and services that violated community standards and terms of service of communication network sources and technologies such as Facebook; and 2) the foregoing exposed the Company to significant financial and reputational risk.

WHAT THIS MEANS TO YOU AS A SHAREHOLDER: If you have suffered a loss in Cognyte you have until May 1, 2023 to petition the court for lead plaintiff status. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU: If you purchased Cognyte securities during the relevant period, you may be entitled to compensation without payment of any out-of-pocket fees.

HOW TO PROTECT YOUR FINANCIAL INTERESTS: For additional information about the CGNT lawsuit, please contact J. Klein, Esq. by telephone at 212-616-4899 or click this link: https://www.kleinstocklaw.com/pslra-1/cognyte-lawsuit-loss-submission-form?id=37687&from=4.

ABOUT KLEIN LAW FIRM
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. The Klein Law Firm is a boutique litigation firm with experience in a wide range of areas including securities law, corporate finance and commercial litigation. Since 2011, our experienced attorneys have achieved superior results for our clients with a personalized focus. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
535 Fifth Avenue
4th Floor
New York City, NY 10017
[email protected]
Telephone: (212) 616-4899
www.kleinstocklaw.com

SOURCE The Klein Law Firm


These press releases may also interest you

at 04:00
Blocktrade, the gamified asset marketplace for everyone, has announced the close of its exclusive Blocktrade Exchange Token (BTEX) sale round, which ran from May 5th to 18th and followed a sold-out pre-sale round earlier this year. A total of ?4.5...

at 04:00
Dedicated gaming and esports edition of DMCC's Future of Trade report finds MENA gaming revenues to hit USD 6 billion in 2027Growth to be accelerated by sector-specific ecosystems in key business hubs, demonstrating the importance of DMCC's Gaming...

at 03:54
The InnoVEX exhibit for startups at COMPUTEX 2023 will be held at Taipei Nangang Exhibition Hall 2 from May 30 to June 2. As a global platform for startups, InnoVEX 2023 will integrate 5G, AIoT, healthcare technology, metaverse and XR, electric...

at 03:51
MediaTek today announced a partnership with NVIDIA to deliver a complete range of in-vehicle AI cabin solutions for the next generation of software-defined vehicles. The collaboration combines the strength of each company's automotive portfolios to...

at 03:48
This is a report from China.org.cn: Quzhou city in Zhejiang province is staging an online exhibition of its products to woo global buyers. The online exhibition mainly showcases the city's flagship products, from caviar, outdoor tents, to doors and...

at 03:30
Abiogen Pharma S.p.A., Italian leading company in the field of osteoarticular and bone metabolism diseases, is pleased to announce the acquisition of a 97,09% stake in EffRx Pharmaceuticals SA, a Swiss company that develops and markets prescription...



News published on and distributed by: